Viking Therapeutics Inc
F:1VT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Viking Therapeutics Inc
F:1VT
|
US |
Viking Therapeutics Inc
Viking Therapeutics is a clinical-stage biotechnology company that develops medicines for metabolic and endocrine diseases. Its main programs are drug candidates for obesity, fatty liver disease, and related disorders. The company does not sell a broad product line today; instead, it works to take experimental treatments through testing and, if successful, toward approval and commercialization. Its business model is built around creating new drug candidates in-house, testing them in clinical trials, and then either selling those medicines itself or partnering with larger drug companies to bring them to market. The people who ultimately matter most are patients and the doctors who treat them, while the near-term business relationships are with regulators, research sites, and potential partners. Like many biotech companies, it makes money only if its programs succeed through development and create licensing, partnership, or product sales opportunities. What makes Viking different is that it focuses on a few high-value disease areas where there is strong medical need and where a successful drug can be very important in care. In biotech, this means the company’s value depends mainly on its scientific pipeline and clinical progress rather than on an existing portfolio of marketed products. That makes it a pure drug-development business, with all the upside and risk that comes with that model.
Viking Therapeutics is a clinical-stage biotechnology company that develops medicines for metabolic and endocrine diseases. Its main programs are drug candidates for obesity, fatty liver disease, and related disorders. The company does not sell a broad product line today; instead, it works to take experimental treatments through testing and, if successful, toward approval and commercialization.
Its business model is built around creating new drug candidates in-house, testing them in clinical trials, and then either selling those medicines itself or partnering with larger drug companies to bring them to market. The people who ultimately matter most are patients and the doctors who treat them, while the near-term business relationships are with regulators, research sites, and potential partners. Like many biotech companies, it makes money only if its programs succeed through development and create licensing, partnership, or product sales opportunities.
What makes Viking different is that it focuses on a few high-value disease areas where there is strong medical need and where a successful drug can be very important in care. In biotech, this means the company’s value depends mainly on its scientific pipeline and clinical progress rather than on an existing portfolio of marketed products. That makes it a pure drug-development business, with all the upside and risk that comes with that model.
Pipeline momentum: Viking said both Phase III VANQUISH obesity trials for subcutaneous VK2735 remain on track, with enrollment now complete in VANQUISH-2 and a device transition to an auto-injector progressing smoothly.
Oral program: The company plans to move oral VK2735 into Phase III in the fourth quarter of 2026, later than the prior expectation implied by earlier discussions, but management said the timing shift reflects manufacturing and scale-up work rather than a change in conviction.
Maintenance strategy: Viking expanded its maintenance study from 4 to 8 subcutaneous cohorts so it can better choose doses for the VANQUISH extension studies; subcutaneous maintenance data are expected in the third quarter, with oral maintenance data in the first half of next year.
Cash and spending: First-quarter R&D spending jumped to $115.2 million from $41.4 million a year ago, driving a net loss of $158.3 million, while the company ended the quarter with $603 million in cash, cash equivalents and short-term investments.
Commercial setup: Viking added a first Chief Commercial Officer, Neil Aubuchon, as it prepares for possible commercialization of VK2735 and highlighted continued investment in supply chain, manufacturing and quality.
Amylin program: The company filed an IND for VK3019 and expects to start a Phase I trial later this quarter, beginning with single-agent SAD and MAD studies before thinking about combination work.
